Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250692 | 1.00 | ATM (0.43) | ATML3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26417010 | 1.00 | ATM (0.43) | ATML3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12250719 | 0.87 | ESR1 (0.46) | SMN1; SMN2KMT2AMMEACEACE2 | |
| SCHEMBL13630710 | 0.87 | ESR1 (0.46) | SMN1; SMN2KMT2AMMEACEACE2 | |
| SCHEMBL12250708 | 0.87 | ESR1 (0.46) | SMN1; SMN2KMT2AMMEACEACE2 | |
| SCHEMBL23065772 | 0.86 | HDAC1 (0.45) | NPC1RAB9ASMN1; SMN2ACACBKMT2A | |
| SCHEMBL23974737 | 0.86 | LOXL2 (0.40) | SMN1; SMN2CYP24A1MMEACEACE2 | |
| SCHEMBL14011032 | 0.86 | NOS2 (0.45) | HPGDACEUSP30 | |
| SCHEMBL12250727 | 0.86 | NOS2 (0.45) | HPGDACEUSP30 | |
| SCHEMBL25454926 | 0.86 | CA2 (0.39) | NPC1RAB9ACYP24A1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9593156-B2 | Insulin analog dimers | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-9573987-B2 | CTP-based insulin analogs for treatment of diabetes | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160340400-A1 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9458220-B2 | Single-chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20150299285-A1 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-10-22 | — | — | US | disclosed |
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2014-10-16 | — | — | US | disclosed |
| US-8697632-B2 | Amide based insulin prodrugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2013-08-08 | — | — | US | disclosed |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | disclosed |
| US-20130123171-A1 | AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120021982-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | disclosed |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090281032-A1 | Modified CCK peptides | UNIVERSITY OF ULSTER (GB) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | ATM 4237/4885L3MBTL1 4426/4885NPC1 839/4885 |
| US-20130123171-A1 | AMIDE-BASED INSULIN PRODRUGS | IAPP, IDE, DNPEP | ATM 2757/4885L3MBTL1 1351/4885NPC1 3734/4885 |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | IAPP, IDE, DNPEP | ATM 2817/4885L3MBTL1 1489/4885NPC1 3619/4885 |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | ATM 4237/4885L3MBTL1 4426/4885NPC1 839/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ATM 1880/4885L3MBTL1 992/4885NPC1 85/4885 |
| US-20120021982-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION | APOB, FABP3, TNNT2 | ATM 4097/4885L3MBTL1 4604/4885NPC1 458/4885 |
| US-20150299285-A1 | CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES | CTPS1, CTPS2, INSR | ATM 2236/4885L3MBTL1 2166/4885NPC1 2032/4885 |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | ATM 4276/4885L3MBTL1 4353/4885NPC1 920/4885 |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ATM 3210/4885L3MBTL1 382/4885NPC1 4382/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | ATM 1880/4885L3MBTL1 992/4885NPC1 85/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | ATM 4006/4885L3MBTL1 1817/4885NPC1 776/4885 |
| US-20090281032-A1 | Modified CCK peptides | CCKAR, PTMS, VIP | ATM 472/4885L3MBTL1 839/4885NPC1 4431/4885 |
| US-20110245164-A1 | YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, INSR, IGFBP1 | ATM 2917/4885L3MBTL1 78/4885NPC1 4770/4885 |
| US-20160340400-A1 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | ATM 3368/4885L3MBTL1 460/4885NPC1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.